Erasca (ERAS)

• Market cap: $3.08B
• 1 day: -48.3%
• 5 days: -56.21%
• 1 month: -33.73%
• 3 months: -2.27%
• 6 months: 305.74%
• Year to date: 175.77%
• 1 year: 607.14%
• 5 years: -43.2%
• 10 years: -43.2%
• Sector: Healthcare
• Industry: Biotechnology

About: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Employees: 103